Moretti, A. et al. Nat. Med. (2020) 10.1038/s41591-019-0738-2
Duchenne muscular dystrophy (DMD) is an inherited and eventually fatal myopathy that affects about 1 in 5000 newborn boys. The mutation responsible, a frameshift mutation affecting the gene that produces the dystrophin protein in muscles, maybe however be amenable to gene therapy. Trials in patients have been limited, but CRISPR/Cas9-based therapies delivered via adeno-associated virus vectors have shown promise in mouse and canine models. New work from researchers in Munich adds another large animal: the pig.
The team generated a pig model of DMD; these animals do not express dystrophin and display muscle weakness, signs of cardiac myopathy, and experience premature death. A CRISPR/Cas9-based therapy, delivered intravenously, was able to restore dystrophin expression in muscles such as the diaphragm and heart and prolong lifespans in the pig model.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Neff, E.P. DMD treatment in pigs. Lab Anim 49, 73 (2020). https://doi.org/10.1038/s41684-020-0501-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41684-020-0501-9